University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (morning panel discussion)

Taylor JM Conlon AS Elliott MR . Surrogate assessment using principal stratification. Clin Trials 2015; 12: 317–322.

Baker SG Kramer BS . Evaluating surrogate endpoints, prognostic markers, and predictive markers: some simple themes. Clin Trials 2015; 12: 299–308.

Ellenberg SS . Surrogate endpoints. Br J Cancer 1993; 68: 457–459.

Hsu JY Kennedy EH Roy JA . Surrogate markers for time-varying treatments and outcomes. Clin Trials 2015; 12; 309–316.

Byar D Corle DK . Selecting optimal treatment in clinical trials using covariate information. J Chronic Dis 1977; 30: 445–459.

Cai T Tian L Wong PH . Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostat 2011; 12: 270–282.

Porsteinsson AP Drye LT Pollock BG . Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 2014; 311: 682–691.

Rein L . Assessing treatment effect heterogeneity in the Citalopram for Agitation in Alzheimer’s Disease clinical trial: a subgroup analysis to guide personalized treatment selections. Master of Science Thesis, Johns Hopkins University, Baltimore, MD, 2014.

Zhang B Tsiatis AA Laber E . A robust method for estimating optimal treatment regimes. Biometrics 2012; 68: 1010–1018.

Pearl J . Causal diagrams for empirical research. Biometrika 1995; 82: 669–710.

Jo B Wang CP Ialongo NS . Using latent outcome trajectory classes in causal inference. Stat Interface 2009; 2: 403–412.

Robins JM Greenland S . Identifiability and exchangeability for direct and indirect effects. Epidemiology 1992; 3: 143–155.

Pearl J Bareinboim E . External validity and transportability: A formal approach. 2011 JSM Proceedings, Miami Beach FL, July 30–August 4, 2011, pp. 157–171.

Pearl J Bareinboim E . Transportability of causal and statistical relations: a formal approach. In: Burgard W Roth D (eds) Proceedings of the twenty-fifth national conference on artificial intelligence. Menlo Park, CA: AAAI Press, 2011, pp. 247–254.

Bareinboim E Pearl J . Transportability of causal effects: completeness results. In: Hoffmann J Selman B (eds) Proceedings of the twenty-sixth national conference on artificial intelligence. Menlo Park, CA: AAAI Press, 2012, pp. 698–704.

Bareinboim E Pearl J . A general algorithm for deciding transportability of experimental results. J Causal Inference 2013; 1: 107–134.

Bareinboim E Pearl J . Causal transportability with limited experiments. In: DesJardins M Littman M (eds) Proceedings of the twenty-seventh national conference on artificial intelligence. Menlo Park, CA: AAAI Press, 2013, pp. 95–101.

Bareinboim E Pearl J . Transportability from multiple environments with limited experiments: completeness results. In: Welling M Ghahramani Z Cortes C . (eds) Advances of neural information processing 27 (NIPS Proceedings). La Jolla, CA: NIPS, 2014, pp. 280–288.

Gruber S Van der Laan MJ . Consistent causal effect estimation under dual misspecification and implications for confounder selection procedures. Stat Methods Med Res. Epub ahead of print 23 February 2012. DOI: 10.1177/0962280212437451.

Prentice RL . Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431–440.